- Pfizer, in a rare COVID-19 setback, dumps Paxlovid's intravenous sibling to leave ACTIV-3 future in doubt
- UPDATE: Editas suddenly terminates Chief Medical Officer Lisa Michaels without explanation
- Ovid pens deal to offload twice-failed former lead program, positioning Healx to write new chapter in fragile X
- After reaching a high with $12B valuation, Biosplice lays off staff and axes baldness program
- Congruence pulls in $50M series A to build a team of 'drug hunters' to go after rare disease targets
- Amgen's COVID-19 manufacturing deal with Lilly helped compensate for lagging Aimovig, Enbrel in Q4
- CooperSurgical to acquire Cook Medical's IVF, OB-GYN businesses for $875M
- Centene posts $599M in profit for Q4 2021 a year after posting a loss in Q4 2020
- New CRISPR tool maps out routes to better immune cell therapies for cancer, autoimmune diseases
- Bristol Myers Squibb doles out $8M in new grants to improve health equity with cardiovascular, oncology focus
- Senators introduce bipartisan bill to extend patient access to telehealth through 2024
- DNA-based HIV vaccine produces critical tier-2 neutralizing antibodies in mouse model
- FDA must shore up plans for surprise foreign inspections, rev up hiring of overseas investigators, GAO says
Featured Story | By Nick Paul Taylor Add Pfizer to the long list of victims of ACTIV-3. While the Big Pharma has enjoyed unparalleled success in COVID-19, it was unable to buck the trend in the NIH study of hospitalized patients and has stopped development of Paxlovid’s intravenous sibling PF-07304814. read more |
| |
|---|
|
Top Stories By Kyle LaHucik Editas Medicine has fired Chief Medical Officer Lisa Michaels, M.D., just 15 months into her tenure at the gene editing company. read more By Nick Paul Taylor Ovid Therapeutics has found a potential buyer for its onetime lead program. A little more than one year after gaboxadol’s value-crushing phase 3 flop, Healx has stepped in to see whether it can write another chapter in the long, failure-strewn history of the neurological disease drug. read more By Kyle LaHucik After reaching a $12 billion valuation in 2018, Biosplice appears to be falling back down to Earth, and its workforce is taking the brunt. The company is laying off 41 workers and has culled a male pattern baldness drug from its pipeline. read more By Sophia Sorensen A new biotech called Congruence Therapeutics just snagged $50 million to build a new team of "drug hunters" focused on protein misfolding to go after rare diseases. read more By Kevin Dunleavy As Amgen struggles to find growth from its own drugs, the company got a nice late-2021 revenue bump from its manufacturing partnership with Eli Lilly. read more By Conor Hale Cook’s subsidiaries will continue to manufacture products for CooperSurgical during a two-year transition. read more By Paige Minemyer Centene Corporation brought in $599 million in profit for the fourth quarter of 2021 after posting a loss in the fourth quarter of 2020. read more By Angus Liu A new CRISPR platform designed by UCSF allowed researchers to perform genomewide CRISPR screens in primary human T cells like never before. The system identified several previously unknown regulators of cytokine production, which could aid the design of next-generation cell therapies, the team said. read more By Max Bayer Bristol Myers Squibb announced nearly $8 million in new grants as a part of its pledge to spend $150 million over five years to address health disparities. The company intends for recipients of this round of grants to bolster community health workers and patient navigators. read more By Heather Landi Two U.S. senators introduced bipartisan legislation Monday to extend current Medicare telehealth reimbursement waivers an additional two years following the end of the public health emergency. read more By Kyle LaHucik Researchers at the Wistar Institute said they were able to elicit an important group of antibodies for fighting HIV in mice. The findings could lead to "more advanced HIV vaccine concepts," the researchers reported in Nature Communications. read more By Fraiser Kansteiner To tackle three big hurdles facing its inspection work overseas, the FDA needs to develop “tailored strategies and time frames” to recruit investigators for its foreign inspection workforce, the Government Accountability Office said Monday. Likewise, the regulator needs to make a roadmap for surprise foreign inspections, the agency said. read more Resources Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Blue Matter, strategic consultants in the life sciences What’s in store for the CNS therapeutics market in 2022? This paper looks ahead in Alzheimer’s, Parkinson’s, DMD, psychiatric disorders, pain, and more. Sponsored by: Thermo Fisher Scientific Learn how a CDMO partnered with Thermo Fisher Scientific to manage high-volume process liquid and buffer preparation scale-up. Download the free case study from Thermo Fisher Scientific Sponsored by: Thermo Fisher Scientific A variety of genetic analysis methods are valuable in ensuring that ex vivo human cells to be used for cell-based therapies are correctly identified, have the correct characteristics, and are free of contaminants. Sponsored by: IQVIA Learn how to elevate your omnichannel marketing strategy with Next Best - a combination of data and analytics, deployed to facilitate decision making. Sponsored by: Catalent Biologics Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Thermo Fisher Scientific Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific Sponsored by: Box Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization. Fierce Drug Safety Summit March 8-9, 2022 | Virtual Fierce BD&L Summit for Life Sciences March 15-16, 2022 | San Francisco, CA Fierce Promotional Review Committee Compliance and Best Practices Summit April 12-14, 2022 | New Brunswick, NJ Fierce Medical Affairs Strategic Summit (MASS) East April 12-14, 2022 | New Brunswick, NJ Fierce Trial Master File Summit May 2-4, 2022 | New Orleans, LA & Streaming Live Fierce Leaders in Life Sciences Forum May 24, 2022 | Complimentary Virtual Event Fierce Health IT Summit May 24, 2022 | Virtual Event Fierce Digital Pharma Engage June 14-15, 2022 | Huntington Beach, CA Fierce Pharma PR & Communications Summit West June 14-15, 2022 | Huntington Beach, CA Fierce Digital Pharma Innovation Week June 21-23, 2022 | Virtual Event Fierce Biotech Next-Gen Week June 29-30, 2022 | Virtual Event Fierce Pharma PR & Communications Summit July 2022 | Location TBD (NYC Metro Area) Fierce MedTech Summit August 8-9, 2022 | Minneapolis, MN Fierce Biotech Summit September 13-14, 2022 | Boston, MA Promotional Review Committee Compliance and Best Practices Summit West (PRC West) September 2022 | San Diego, CA Medical Affairs Strategic Summit (MASS West) September 2022 | San Diego, CA Fierce Digital Pharma East October 18-20, 2022 | Philadelphia, PA & October 25-28, 2022 | Virtual Event Fierce Pharma Marketing Awards October 19, 2022 | Philadelphia, PA Fierce Biotech Cell & Gene Therapy Forum October 19, 2022 | Virtual Event Fierce European Trial Master File Summit October 31- November 2, 2022 | London Fierce Pharma Meeting Professionals Summit November 2-3, 2022 | Atlantic City, NJ Fierce Diversity, Equity & Inclusion Forum November 15-16, 2022 | Virtual Event Fierce Launch Readiness for Medical Affairs & Communications Teams Summit November 30-December 1, 2022 | Virtual Event Fierce New Product Planning Summit November 30 - December 1, 2022 | Virtual Event Fierce JPM Week 2023 January 2023 | San Francisco, CA & Virtual | 
